In this video, Kevin McVary, MD, FACS, discusses the future research stemming from the study, “Preservation of sexual function 5-years after water vapor thermal therapy for benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association Annual Meeting. McVary is a professor of urology and director of the Center for Male Health at Loyola University Medical Center, Maywood, Illinois.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.